Aldeyra Therapeutics to Host Investor Roundtable QA
Aldeyra Therapeutics to Host Investor Roundtable QA
Event Scheduled for Thursday, June 20 at 8:00 a.m. ET
活動定於2019年6月20日 上午8:00美國東部時間
LEXINGTON, Mass.--(BUSINESS WIRE)--Jun. 12, 2024-- Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced that the company will host an Investor Roundtable Q&A via webcast on Thursday, June 20, 2024 at 8:00 a.m. ET.
美國馬薩諸塞州列剋星敦市--（美國商業資訊)--2024年6月12日--Aldeyra Therapeutics, Inc.（納斯達克: ALDX）（Aldeyra）是一家專注於開發創新療法，致力於治療免疫介導和代謝性疾病的生物技術公司，今天宣佈該公司將於2024年6月20日星期四東部時間上午8:00通過網絡直播舉辦投資者圓桌問答活動。
The call will include prepared remarks from Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer, followed by a Q&A session. The call will be open to all current and prospective Aldeyra shareholders, and participants will be able to submit questions through the webcast portal during the event. In addition, beginning Monday, June 17, investors will be able to submit questions ahead of the call via email to investorrelations@aldeyra.com.
該會議將包括來自Todd C. Brady, M.D.博士，Ph.D.總裁兼首席執行官的發言，之後是問答環節。這次電話會議將對所有現有和潛在的Aldeyra股東開放，參與者將能夠在活動期間通過網絡直播門戶提交問題。此外，從6月17日星期一開始，投資者們將能夠通過電子郵件事先提交問題。investorrelations@aldeyra.com.
A live audio webcast and slide presentation will be accessible from the "Investors & Media" section of the Aldeyra website at https://ir.aldeyra.com/. A replay will be available for 90 days following the event.
現場音頻網上直播和幻燈片演示將從Aldeyra網站的“投資者和媒體”(Investors & Media)部分處獲得。網站鏈接爲：https://ir.aldeyra.com/。活動後90天內，將提供重播。關於Aldeyra回放將在活動結束後90天內提供。
About Aldeyra
Aldeyra Therapeutics is a biotechnology company devoted to discovering innovative therapies designed to treat immune-mediated and metabolic diseases. Our approach is to develop pharmaceuticals that modulate protein systems, instead of directly inhibiting or activating single protein targets, with the goal of optimizing multiple pathways at once while minimizing toxicity. Our product candidates include RASP (reactive aldehyde species) modulators ADX-629, ADX-246, ADX-248, and chemically related molecules for the potential treatment of immune-mediated and metabolic diseases. Our late-stage product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the potential treatment of retinitis pigmentosa.
關於Aldeyra
Aldeyra Therapeutics是一家專注於發現旨在治療免疫介導和代謝性疾病的創新療法的生物技術公司。我們的方法是開發調節蛋白質系統的藥品，而不是直接抑制或激活單個蛋白靶標，以期在最小化毒性的同時優化多條途徑。我們的產品候選包括RASP（活性醛類物質）調節劑ADX-629、ADX-246、ADX-248和與之化學相關的分子，用於潛在治療免疫介導和代謝性疾病。我們的後期產品候選包括reproxalap，一種RASP調節劑，可潛在治療乾眼病和過敏性結膜炎，以及ADX-2191，一種新型眼內注射甲氨蝶呤製劑，可潛在治療視網膜色素變性症。
View source version on businesswire.com: https://www.businesswire.com/news/home/20240612329514/en/
在businesswire.com上查看原始版本businesswire.com: https://www.businesswire.com/news/home/20240612329514/en/
Investor & Media:
David Burke
Tel: (917) 618-2651
investorrelations@aldeyra.com
投資者和媒體：
David Burke
電話：(917) 618-2651
investorrelations@aldeyra.com
Source: Aldeyra Therapeutics, Inc.
來源：Aldeyra Therapeutics股份有限公司